Pharmabiz5d
Claypond Capital appoints Dr Shravan Subramanyam to lead its medical technology platform
Claypond Capital, the family investment office of Manipal Group chairman Ranjan Pai, has roped in former managing director of Wipro-GE Healthcare Shravan Subramanyam to lead its medical technology ...
Pharmabiz5d
CDSCO establishes Sub-Zonal Office in Bhubaneswar, boosting Odisha’s pharmaceutical sector
In a significant move to enhance drug regulation and monitoring in Odisha, the Central Drugs Standard Control Organisation (CDSCO) has announced the establishment of a Sub-Zonal Office in Bhubaneswar.
Pharmabiz5d
eMBR Genomics partners with Axio BioPharma to make MKLP1 Pro antibodies commercially available
In a milestone for cellular research, eMBR Genomics and Axio BioPharma announce the first commercial availability of MKLP1 Pro antibodies, KIF23 gene – the same tools used by the world’s leading ...
Pharmabiz5d
Indian healthcare sees medical networking as catalyst for quality services in remote regions
The Indian healthcare sector sees emergence of medical networking to revolutionise quality services in remote regions. This is despite the resource and infrastructural constraints leading to the ...
Pharmabiz5d
Santhera enters supply and distribution agreement with Clinigen Group for Agamree to treat patients with Duchenne muscular dystrophy
Santhera Pharmaceuticals announces the signing of an exclusive agreement with Clinigen Group to manage the supply and distribution of Agamree (vamorolone) in countries where the product is not ...
Pharmabiz5d
JCR Pharma & Modalis validate initial proof of concept in a joint research programme for development of a novel gene therapy for a CNS disease
JCR Pharmaceuticals Co., Ltd., a global specialty pharmaceuticals company, and Modalis Therapeutics Corporation, a forerunner in the field of epigenetic medicine, announced that they have validated ...
Pharmabiz5d
SunAct Cancer Institute ties up with Singapore’s CytoMed for phase 2 clinical trials on innovative Gamma Delta T-cell cancer therapy in India
SunAct Cancer Institute is excited to announce the start of phase 2 clinical trials on a groundbreaking treatment called Gamma Delta T-cell therapy. This trial, conducted in collaboration with CytoMed ...
Pharmabiz6d
Eton Pharma acquires Galzin, an US FDA approved treatment of ultra-rare metabolic condition of Wilson disease
Eton Pharmaceuticals, Inc, an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, announced that it has acquired Galzin (zinc acetate). “This ...
Pharmabiz5d
US FDA grants orphan drug designation to NMD Pharma’s NMD670 to treat patients with Charcot-Marie-tooth disease
NMD Pharma A/S, a clinical-stage biotech company dedicated to developing novel and improved treatments for patients living with neuromuscular diseases, announces that the US Food and Drug ...
Pharmabiz5d
CRIUS Group adopts 100%AI-based project implementation
CRIUS Group has emerged as India’s first contract manufacturing organization (CMO) to adopt 100% AI-based project implementation. This move leverages the NutrifyGenie Integrated AI platform, marking a ...
Pharmabiz6d
Parliamentary panel asks DoE to furnish justification on denying proposal for setting up of NIMERs
Expressing its concern over the Department of Expenditure's (DoE) decision to turn down the Department of Pharmaceuticals (DoP)’s proposal for setting up separate National Institutes for Medical ...
Pharmabiz6d
Bayer announces Federal Court of Australia brings an end to Roundup litigation
The Federal Court of Australia brought an end to the last Roundup case in Australia, closing all pending injury litigation there. The Court granted the plaintiffs’ request to discontinue the Fenton ...